Sanofi Announces the Result of Sarclisa (isatuximab)+ KRd in P-III Trial to Treat Multiple Myeloma
Shots:
- The P-III study evaluating the safety and efficacy of Sarclisa+carfilzomib, lenalidomide & dexamethasone vs KRd alone in transplant-eligible patients (n=302) with newly diagnosed multiple myeloma across 8 countries 42 sites in the EU
- The result of the 1EP study depicted MRD negativity of 77% vs 67% & 67% vs 48% at the sensitivity of 10-5 & 10-6 with consistent results in all subgroups. The safety & tolerability of the drug were found to be consistent with previous data
- Sarclisa, a mAb, targets the CD38 receptor on MM cells, triggering various antitumor effects. It induces programmed cell death & has immunomodulatory properties
Ref: Sanofi | Image: Sanofi
Related News:- Sanofi Reports Results for Sarclisa (Isatuximab) in P-III Trial for the Treatment of Newly Diagnosed Multiple Myeloma Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
